Summary
A total of 130 primary cases with superficial bladder cancer were entered in the prospective randomized group study. The prophylactic treatments compared consisted in intravesical instillation of adriamycin (20 mg/40 ml or 30 mg/30 ml), mitomycin C (20 mg/40 ml) or thio-TEPA (30 mg/30 ml), and noninstillation treatments with etretinate or tegafur; control patients were also studied. All agents were administered for 2 years. Recurrences were significantly suppressed in the instillation groups compared with control and non-instillation groups. Significant suppression of recurrence was observed in stage 1 or grade 2 disease treated with prophylactic instillation administered over the first 24 months of a 48-month observation period. These results may indicate the clinical usefulness of prophylactic instillation, but the long-term effect of intravesical instillation is still uncertain. A long-term follow-up study is therefore necessary.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Esquivel EL Jr, Mackenzie AR, Whitmore WF Jr (1965) Treatment of bladder tumors by instillation of thiotepa, actinomycin D or 5-fluorouracil. Invest Urol 2: 381
Issell BF, Prout GR Jr, Soloway MS, Cummings KB, Brannen G, Veenema R, Flanagan M, Block NL, Summers JL, Levin EA, Defuria MD (1984) Mitomycin C intravesical therapy in noninvasive bladder cancer after failure on thiotepa. Cancer 53: 1025
Jones HC, Swinney J (1961) Thio-TEPA in the treatment of the urinary bladder. Lancet II: 615
Koontz WW Jr, Prout GR Jr, Smith W, Frable WJ, Minnis JE (1981) The use of intravesical thio-TEPA in the management of non-invasive carcinoma of the bladder. J Urol 125: 307
Murasaki G, Miyata Y, Babaya K, Arai M, Fukushima S, Ito N (1980) Inhibitory effect of an aromatic retinoic acid analog on urinary bladder carcinogenesis in rats treated with N-butyl-N-(4-hydroxybutyl) nitrosamine. Gann 71: 333
Niijima T, Koiso K, Akaza H, and Japanese Urological Cancer Research for Adriamycin (1983) Randomized clinical trial on chemoprophylaxis of recurrence in cases of superficial bladder cancer. Cancer Chemother Pharmacol 11 [Suppl]: S79
Okajima E, Hiramatsu T, Kihoin K, Ijuin M, Hirao Y, Ohara S, Babaya K, Tanaka M, Maruyama Y (1982) Effect of tegafur (FT-207) on urinary bladder tumors in rats induced by N-butyl-N-(4-hydroxybutyl)nitrosamine: II. Influence of FT-207 by oral administration on development of urinary bladder. Jpn Cancer Chemother 9: 473
Schulman CC, Robinson M, Denis L, Smith P, Viggiano G, de pauw M, Dalesio O, Sylvester R and members of the EORTC Genito-Urinary Tract Cancer Cooperative Group (1982) Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, an epipodophyllotoxin (VM 26) and TUR alone. Eur Urol 8: 207
Soloway MS (1980) Rationale for intensive intravesical chemotherapy for superficial bladder cancer. J Urol 123: 461
Sporn MB, Squire RA, Brown CC, Smith JM, Wenk ML, Springer S (1977) 13-cis-Retinoic acid: inhibition of bladder carcinogenesis in the rat. Science 195: 487
Studer UE, Biedermann C, Chollet D, Karrer P, Kraft R, Toggenburg H, Vonbank F (1984) Prevention of recurrent superficial bladder tumors by oral etretinate: preliminary results of a randomized, double blind multicenter trial in Switzerland. J Urol 131: 47
Veenema RJ, Dean AL, Uson AC, Roberts M, Longo F (1969) Thiotepa bladder tumors instillations: Therapy and prophylaxis for superficial bladder tumours. J Urol 101: 717
Author information
Authors and Affiliations
Additional information
Department of Urology, Saiseikai Chuwa Hospital
Rights and permissions
About this article
Cite this article
Hirao, Y., Okajima, E., Ohara, S. et al. Prophylactic treatment for superficial bladder cancer following transurethral resection. Cancer Chemother. Pharmacol. 20 (Suppl 1), S85–S90 (1987). https://doi.org/10.1007/BF00262494
Issue Date:
DOI: https://doi.org/10.1007/BF00262494